The matrix metalloproteinases appear to play an important role in the development and progression of atherosclerotic lesions. We studied the C-1562T polymorphism of the gelatinase B promoter in relation to coronary artery disease and restenosis after a percutaneous coronary intervention (PCI) in Koreans. To determine the frequency of the C-1562T allele, we examined 63 patients with coronary artery disease who underwent both PCI and 6-month follow-up coronary angiograms (CAGs), and 67 control patients with a normal CAG with respect to their clinical data and genotype. Frequencies of the C/C homozygotes and the non-C/C heterozygotes and homozygotes (C/T and T/T) were 94% and 6% in the normal CAG group, and 76.2% and 23.8% in the patient group, respectively. This gave a relative risk of 0.203 (95% CI: 0.063-0.651, P ϭ 0.005) for coronary artery disease when the C/C genotype was compared with the non-C/C genotype. In the patient groups, the allele frequencies of the C/C and non-C/C were 80% and 20% in the nonrestenotic subgroup, and 71.4% and 28.6% in the restenotic subgroup (P ϭ 0.554). No T/T homozygote was found in any of the groups. We conclude that C/C homozygosity is a potential genetic protective factor for coronary artery disease in Koreans.
Introduction
The matrix metalloproteinases (MMPs), a family of zincdependent enzymes that have proteolytic activity against connective tissue proteins, appear to play an important role in the development and progression of atherosclerotic lesions and are contributors to intimal growth and restenosis after stenting (Bendek et al. 1996; Ye 2000; Feldman et al. 2001) . Three functional polymorphisms of MMPs are known to be related to coronary artery disease, i.e., MMP-3, MMP-9, and MMP-12 (Ye et al. 1995; Terashima et al. 1999; Zhang et al. 1999; Jormsjo et al. 2000) .
Gelatinase B (also known as 92-kDa type IV collagenase, or MMP-9) is a member of the MMP family. Gelatinase B is found to be highly expressed in the disruption-prone region of atherosclerotic plaques. It has broad substrate specificity, being particularly active against gelatins and type IV collagen; therefore, it plays a key role in extracellular matrix degradation. This is required for cell migration into the intima after an arterial injury (Pauly et al. 1994; Newby et al. 1994) .
The functional C-1562T polymophism of the gelatinase B promoter was studied for its effects on atherosclerotic severity in a patient with coronary artery disease (Zhang et al. 1999 ), but no definite relation to coronary artery disease could be found in the general population. Consequently, we studied the C-1562T polymorphism of the gelatinase B promoter in its relation to coronary artery disease by comparing a proven normal coronary angiogram (CAG) group with a coronary artery disease patient group and also by examining the development of restenosis after a percutaneous coronary intervention (PCI) in the patient group.
Patients and methods

Patients and control individuals
A total of 130 subjects who were available for genomic DNA analysis were enrolled in this study. All participants were Korean nationals. The study population was composed of 63 patients with coronary artery disease who had undergone both PCI and a 6-month CAG follow-up, as well as 67 control patients in a normal CAG group who had atypical chest pains and were admitted to the Seoul National University Hospital between January 1997 and July 2001. None of the normal CAG control individuals had insignificant coronary artery stenosis. Insignificant coronary artery stenosis was excluded in this study. The coronary artery disease patient group expressed a stenosis of Ն50% in at least one epicardial artery and ischemic chest pain. The restenotic subgroup was defined as having a restenosis of Ն50% at the PCI site and a clinically redeveloped chest pain. We also examined clinical and laboratory characteristics such as age, gender, diabetes, hypertension, smoking, total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. All patients had given informed consent for genetic and clinical examination before CAG.
Analysis of the polymorphism
Genomic DNA was extracted from peripheral blood leukocytes according to a standard protocol (Sambrook et al. 1989 ). We performed the polymerase chain reaction (PCR) by using the primers that were designed according to a previous study (Zhang et al. 1999 ). Subsequently, the PCR products were digested with an appropriate restriction enzyme, BbuI, and fractionated on a 1.5% agarose gel. The T allele at the Ϫ1562 polymorphic site generated two fragments using BbuI. Genotypes were scored according to the pattern of the DNA bands.
Statistical analysis
Data were analyzed using Statistical Package for the Social Sciences statistical software.
2 analysis was used to test for the deviation in the genotype distribution of the HardyWeinberg equilibrium and the Fisher's exact test was used to determine whether there was any significant difference in genotype frequencies between normal CAG control group and patient groups. The 2 test and the one-way analysis of variance (ANOVA) test was used for a clinical and laboratory characteristic analysis among the groups. The value of P Ͻ 0.05 was taken to be statistically significant.
Results
The characteristics of the normal CAG subjects and the patients who were subgrouped according to the presence of restenosis are shown in Table 1 . There were no significant differences in the clinical and laboratory characteristics between the groups. The genotypic and allelic frequencies of the C-1562T polymorphism of the gelatinase B promoter gene are summarized in Table 2 . We did not find a T/T genotype in this study. These data are consistent with the distribution predicted by the Hardy-Weinberg equilibrium (the T/T allele was expected in 0.69 persons among the 130 subjects, P value: 0.67).
The allele frequency in normal Korean CAG subjects was different from that which has been previously reported in Caucasians, but the frequency in the coronary artery disease patient population was similar to Caucasian patients (Zhang et al. 1999) . In healthy Caucasians, the frequency of the C allele was 0.87 and in Caucasian coronary artery disease patients the frequency was 0.86. In Koreans, the C/ C genotype was significantly more frequent in normal CAG subjects than in coronary artery disease patients. The odds ratio of the C/C versus the non-C/C genotype for coronary artery disease was significantly low. The frequency of the C/ C genotype in coronary artery disease patients was similar to that of Caucasian patients because the C/C genotype was reported to be 73.2% (Zhang et al. 1999) . However, in comparing the nonrestenotic group with the restenotic group, no significant genotypic difference was found (see Table 3 .)
Discussion
At least 20 human MMPs have been identified. Some can be potentially implicated in both the atherogenic process and in the precipitation of acute coronary syndromes as a result of the regulation of connective tissue remodeling process (Dollery et al. 1995) . There are a number of regulatory mechanisms that can influence the ultimate impact of an MMP on extracellular matrix degradation. It appears that, for most MMPs, the key step is a transcriptional regulation because most MMP genes are expressed only when there is active physiological or pathological tissue remodeling taking place (Matrisian 1990; Fini et al. 1998 ). Expression of gelatinase B is also regulated primarily at the transcription level. The C-1562T polymorphic site is known to be an important regulatory element that appears to be a binding site for a transcription repressor protein, switching from C to T, which results in the loss in the binding of the nuclear protein to this region of the gelatinase B gene promoter and an increase in the transcriptional activity in macrophages (Zhang et al. 1999 ).
An association of the C-1562T polymorphism with the degree of severity of coronary atherosclerosis was detected in a Caucasian study, but there was not a definite association with the development of atherosclerosis when normal subjects were compared with patients (Zhang et al. 1999) . In comparison with the Caucasian study, the normal control subjects of the present study had normal CAGs and mainly atypical chest pain. We excluded subjects who had an insignificant coronary lesion, so that the normal control subjects of this study were a typically normal CAG control population and not just a normal healthy population. In addition, baseline characteristics such as lipid levels and clinical risk factor for coronary artery disease were not significantly different between the normal control group and the patient groups. In this study, we identified the C/C genotype, and a low transcriptional activity, that is associated with the absence of atherosclerosis when we compared the coronary artery disease patients with the normal Korean CAG control subjects. Although the precise underlying mechanisms are unclear, it is plausible that lower gelatinase B expression associated with the C/C genotype attenuates pathological matrix remodeling in atheroclerotic plaque and smooth muscle migration during atherogenesis. However, we did not observe an association with restenosis after PCI. Our study was limited by a relatively small sample size that has weak statistical power; therefore, we cannot exclude the possibility of obtaining false positive results in the genetic study previously mentioned (Risch 2000) . This finding has a possibility of linkage disequilibrium with another lociassociated atherogenesis.
In conclusion, the C allele and the C/C genotype are predominantly found in Koreans, but the T/T genotype is very rare. The C/C genotype is a possible genetic marker for a protective effect in coronary artery disease, but has no significant effect in restenosis after PCI. Further studies are now indicated to validate the differences that appear to be found between Caucasians and Asians. Table 3 . C/C versus non-C/C (C/T and T/T) in relation to restenosis after PCI PCI restenosis(Ϫ) PCI restenosis(ϩ) (n ϭ 35) (n ϭ 28) C/C 28 (80%) 20 (71.4%) Non-C/C 7 (20%) 8 (28.6%) P value: 0.554 PCI, percutaneous coronary intervention
